[
  {
    "ts": null,
    "headline": "Top Stock Reports for Microsoft, SAP & AMD",
    "summary": "MSFT, SAP, and AMD are driving growth with cloud, AI, and chip innovation despite competitive and cost headwinds.",
    "url": "https://finnhub.io/api/news?id=b9d4a93e2a403656756afcfbd7f571f679ea2c55055bfdccbcfad6caebf0a376",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753735140,
      "headline": "Top Stock Reports for Microsoft, SAP & AMD",
      "id": 136113284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "MSFT, SAP, and AMD are driving growth with cloud, AI, and chip innovation despite competitive and cost headwinds.",
      "url": "https://finnhub.io/api/news?id=b9d4a93e2a403656756afcfbd7f571f679ea2c55055bfdccbcfad6caebf0a376"
    }
  },
  {
    "ts": null,
    "headline": "Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?",
    "summary": "Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=16e09a2924904b5186f21bfebd85e4491089388c7c35e04b6e43dfa6b559fda7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753710004,
      "headline": "Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?",
      "id": 136108326,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=16e09a2924904b5186f21bfebd85e4491089388c7c35e04b6e43dfa6b559fda7"
    }
  },
  {
    "ts": null,
    "headline": "ISRG's Gross Margin Falls on Product Transition and Trade Pressures",
    "summary": "Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.",
    "url": "https://finnhub.io/api/news?id=393091d9e30af250b63607354b1572cd8b400053567d7ab87e5a5bccf4facfa0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753705080,
      "headline": "ISRG's Gross Margin Falls on Product Transition and Trade Pressures",
      "id": 136108215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Intuitive Surgical's Q2 gross margin declines to 67.9% as product mix shifts, new facility costs and tariffs weigh on profitability.",
      "url": "https://finnhub.io/api/news?id=393091d9e30af250b63607354b1572cd8b400053567d7ab87e5a5bccf4facfa0"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Raises PT on Boston Scientific Corporation (BSX) to $125 From $120",
    "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the top low volatility healthcare stocks to buy now. On July 24, RBC Capital raised the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $125 from $120, keeping an Outperform rating on the shares. The analyst told investors in a research note that Boston Scientific Corporation (NYSE:BSX) […]",
    "url": "https://finnhub.io/api/news?id=f0747629f888e6134ad7f3bf7a7dedad8e494a5517588693f1ba07036923c915",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682881,
      "headline": "RBC Capital Raises PT on Boston Scientific Corporation (BSX) to $125 From $120",
      "id": 136108328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific Corporation (NYSE:BSX) is one of the top low volatility healthcare stocks to buy now. On July 24, RBC Capital raised the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $125 from $120, keeping an Outperform rating on the shares. The analyst told investors in a research note that Boston Scientific Corporation (NYSE:BSX) […]",
      "url": "https://finnhub.io/api/news?id=f0747629f888e6134ad7f3bf7a7dedad8e494a5517588693f1ba07036923c915"
    }
  }
]